ENDRA Life Sciences to Present New Photoacoustic Imaging Research at the 2017 World Molecular Imaging Congress
ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a developer of enhanced ultrasound technologies, has been invited to present new photoacoustic imaging research at the 2017 World Molecular Imaging Congress being held on September 13-16, 2017 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
ENDRA Life Sciences Chief Technology Officer Michael Thornton is scheduled to present on Saturday, September 16 at 1:30 p.m. Eastern time in Exhibit Hall A, Poster Session 4.
The poster presentation (P373) entitled, ‘The Effect of Low Frequency Noise Power on Image Quality in Photoacoustic Imaging Systems’ will demonstrate how increasing low frequencies by only 1.5% can increase the Contrast to Noise Ratio (CNR) by 150% thus enabling researchers to see anatomical detail at new depths. Concurrent with the new research, ENDRA will showcase its latest photoacoustic computed tomography system, the Nexus 128+, with proprietary 3D imaging technology in Booth #334.
“The Nexus 128+ provides up to twice the photoacoustic sensitivity of our previous system, the Nexus 128, enabling improved quantitation of preclinical animal models,” said Michael Thornton, ENDRA’s Chief Technology Officer. “We are also experiencing positive momentum with our Nexus 128+ in the international marketplace and look forward to announcing new installations with leading research universities in 2017 and beyond.”
“ENDRA’s continued success with our preclinical photoacoustic CT scanners used by global research scientists underscores our commitment to commercializing leading edge tools, and our plan to bring to market a disruptive technology for the clinical market in 2018,” said Francois Michelon, ENDRA’s CEO.
About WMIC 2017: IMAGinING the Future Call for Abstracts
The WMIC 2017 will feature more than 200 oral presentations and more than 850 scientific poster presentations from world-renowned institutions from around the globe, with keynote sessions on advances that will refine animal models, accelerate research and improve clinical care. The WMIC Scientific Program Committee is currently accepting abstract submissions in the following emphases: Neuroscience; Oncology; Cardiology; Inflammation and Infectious Diseases; Metabolic Diseases; Instrumentation and Computation; Basic Biology and Bioengineering. For more information about WMIC 2017 click here.
Posted September 6, 2017